Vectus Biosystems (ASX:VBS) — Material Events
ASX:VBS · 14 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Vectus Turns XORTX Deal Into $1.56m Profit as VB0004 Moves Toward Phase IbHigh
Vectus reports FY2026 profit after XORTX asset transaction while advancing VB0004 and managing funding risk
18 Sept 2026
·Annual Report
·Unexpected
·82
Vectus Biosystems Advances Renal Drug Deal and Expands Licensing Push in ChinaMedium
Vectus Biosystems Signs Deal with XORTX, Advances Licensing and Commercialisation Efforts
30 Oct 2025
·Quarterly Activities Report and Appendix 4C
·80
Vectus Secures Cardinal Health for US FDA Pathway on VB0004Medium
Vectus appoints Cardinal Health as US FDA regulatory agent for VB0004
13 July 2026
·Regulatory Update
·75
Vectus Biosystems Resumes Trading After Key Drug Deal AnnouncementMedium
Vectus Biosystems reinstated to ASX trading after material transaction announcement
17 Oct 2025
·Reinstatement to Quotation
·75
Vectus Biosystems Trades Renal Drug for US$3M Stake in XORTXMedium
Vectus Biosystems to sell VB4-P5 renal compound to XORTX for US$3M, gains equity stake
17 Oct 2025
·Asset Sale
·75
Vectus Biosystems Nears $4.3M XORTX Deal, Advances Licensing PushMedium
Vectus Biosystems Nears $4.3M Deal with XORTX, Advances Licensing and Cost Cuts
30 Jan 2026
·Quarterly Activities Report and Appendix 4C
·75
Vectus Wins FDA Meeting Pathway for VB0004 Lung Fibrosis ProgramMedium
Vectus receives FDA pre-IND meeting approval for VB0004 IPF program
30 Sept 2026
·Regulatory Development Update
·72
Vectus Raises $0.8M to Boost VB0004 Trial and Drug PipelineMedium
Vectus raises $0.8M to accelerate VB0004 clinical trial and drug development
22 May 2026
·Capital Raising
·70
Vectus Converts VB4-P5 Asset into 9.9% Stake in XORTX TherapeuticsMedium
Vectus completes sale of VB4-P5 renal compound to XORTX, gains 9.9% stake
14 Apr 2026
·Transaction Completion Announcement
·70
Vectus Biosystems Swings to $1.56 Million Profit in FY2026Medium
Vectus Biosystems posts AUD 1.56 million profit for FY2026, reversing prior year loss
31 Aug 2026
·Preliminary Final Report
·Unexpected
·70
Vectus Taps Dr Tara Speranza to Drive VB0004 Clinical and Commercial PushMedium
Vectus appoints Dr Tara Speranza as CEO and CTO with performance-linked incentives
7 May 2026
·Executive Appointment
·70
Vectus Biosystems Cuts Losses, Eyes XORTX Deal to Boost Drug PipelineMedium
Vectus Biosystems reports reduced half-year loss, advances drug commercialisation, and nears sale of renal fibrosis compound to XORTX
26 Feb 2026
·Half Year Report
·70
Vectus Biosystems Halts Trading Ahead of Major Drug Deal RevealMedium
Vectus Biosystems requests ASX suspension pending material transaction announcement
17 Oct 2025
·Suspension from Quotation
·60
Vectus Biosystems Denies Undisclosed Info Amid Sharp Share Price SurgeMedium
Vectus Biosystems denies undisclosed info amid sharp share price rise, confirms ASX compliance
11 Nov 2025
·Response to ASX Price Query
·Unexpected
·60
No articles in this tier for the last 12 months.
Market Mentions
9
- appeared in market wrap coverage
These are market wrap articles where Vectus Biosystems (ASX:VBS) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 40 (28 Sept -> 2 Oct) 2026
3 Oct 2026
Healthcare Wrap - Week 38 (14 Sept -> 18 Sept) 2026
19 Sept 2026
Healthcare Wrap - Week 36 (31 Aug -> 4 Sept) 2026
5 Sept 2026
Healthcare Wrap - Week 29 (13 July -> 17 July) 2026
18 July 2026
Healthcare Wrap - Week 21 (18 May -> 22 May) 2026
23 May 2026